## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.09 indicates fundamental undervaluation. Quality metrics strong (ROE 62%). Caution: momentum weakening (-2.3% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($111.87)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Bearish (Bullish: 1, Bearish: 1)

**1. Schroder Investment Management Group Sells 39,629 Shares of DaVita Inc. $DVA**
- Source: MarketBeat | 20251204T120941 | Somewhat-Bearish | Relevance: 100%
- Schroder Investment Management Group reduced its stake in DaVita Inc. by 36% in the second quarter, selling 39,629 shares and now owning 70,431 shares worth approximately $10.03 million. Despite this, other institutions like Neuberger Berman and Norges Bank increased their holdings, leading to institutional ownership of about 90.12%. Analysts have a "Reduce" consensus rating with an average target price of $148.00, following DaVita's missed quarterly EPS and conservative FY2025 guidance.

**2. DaVita - More Volatile But Better Upside Than Fresenius (NYSE:DVA)**
- Source: Seeking Alpha | 20251203T093000 | Bullish | Relevance: 100%
- DaVita (DVA) is rated a speculative 'Buy' due to undervaluation and its dominant US dialysis network, despite earnings volatility and reliance on Medicare reimbursement. Trading below 11.5x P/E, DVA offers potential double-digit annual returns if it regains historical valuation multiples. Key risks include Medicare rate cuts, earnings misses, and high leverage, necessitating careful position sizing for risk-tolerant investors.

**3. Quantbot Technologies LP Acquires 50,040 Shares of DaVita Inc. $DVA**
- Source: MarketBeat | 20251204T131011 | Somewhat-Bearish | Relevance: 100%
- Quantbot Technologies LP significantly increased its stake in DaVita Inc. (NYSE:DVA) by 1,071.3% in the second quarter, acquiring an additional 50,040 shares, bringing its total to 54,711 shares valued at $7.79 million. This increase comes despite a weakening analyst sentiment, with many firms downgrading the stock and setting a consensus price target of $148.00 against the current trading price of around $119. DaVita missed Q3 EPS expectations but provided FY2025 guidance that analysts anticipate to be met.

**4. Edgestream Partners L.P. Invests $6.38 Million in DaVita Inc. $DVA**
- Source: MarketBeat | 20251204T032541 | Bearish | Relevance: 100%
- Edgestream Partners L.P. has acquired a new stake of 44,754 shares in DaVita Inc. (NYSE:DVA), valued at approximately $6.38 million, representing 0.06% ownership. This comes as DaVita recently missed quarterly earnings expectations and received multiple price target cuts, leading to a consensus "Reduce" rating from analysts. The stock is currently trading near $119, with a market capitalization of $8.41 billion.

**5. DaVita Inc. $DVA Shares Sold by Franklin Resources Inc.**
- Source: MarketBeat | 20251203T190816 | Somewhat-Bearish | Relevance: 99%
- Franklin Resources Inc. reduced its stake in DaVita Inc. (NYSE:DVA) by 51.2% in the second quarter, selling over 26,000 shares. DaVita recently reported Q3 earnings that missed analyst expectations with $2.51 EPS on $3.42 billion revenue, and its FY2025 EPS guidance is set between $10.35-$11.15. The stock has a consensus "Reduce" rating with a target price of $148, and institutional ownership remains high at 90.12%.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($54.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $55M sold (3 transactions in 90 days).
2. High short interest (21.1%, 7.3 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 14.1% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.09 suggests fair value with growth premium. Forward P/E 9.2x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($55.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.1B |
| Beta | 0.99 |
| 52W Range | $113.12 - $179.60 |
| Short Interest | 21.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.09 |
| Forward P/E | 9.2 |
| Current P/E | 11.0 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.7% to -4.0% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.0pp (needs >4.0% for momentum thesis). Below SMA200 (0.86x), long-term trend not supportive. RSI neutral at 40. OFD pattern: -DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.04% (CS: 18) | Weak |
| RSI_14 | 40.2 | Neutral |
| MACD Histogram | 0.14 | Bullish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 0.948x | Below |
| vs SMA200 | 0.859x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $117.39
- **Stop Loss:** $111.87 (4.7% risk)
- **Target:** $128.43 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 90
- **Position Value:** $10,565.10
- **Portfolio %:** 10.57%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*